Literature DB >> 11270934

Interpretation of antibacterial susceptibility reports: in vitro versus clinical break-points.

G W Amsden1, J M Duran.   

Abstract

Currently, antibacterial activity is measured primarily via in vitro laboratory tests. Clinicians rely heavily upon the reported susceptibility gained via in vitro laboratory tests when choosing an antibacterial agent. An evolving concept is to utilise pharmacodynamic and pharmacokinetic drug properties in addition to in vitro susceptibility reports to assess the potential effectiveness of an antibacterial agent against a specific pathogen. This article presents examples of the utility of these concepts in terms of optimal clinical use of common antibacterials as well as more informed interpretation of the in vitro literature.

Mesh:

Substances:

Year:  2001        PMID: 11270934     DOI: 10.2165/00003495-200161020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  11 in total

1.  Pharmacological considerations in the emergence of resistance.

Authors:  G W Amsden
Journal:  Int J Antimicrob Agents       Date:  1999-03       Impact factor: 5.283

Review 2.  Pneumococcal macrolide resistance--myth or reality?

Authors:  G W Amsden
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

3.  Single daily dose of aminoglycosides--a concept whose time has not yet come.

Authors:  J S Bertino; J C Rotschafer
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

4.  Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Authors:  P D Lister; C C Sanders
Journal:  J Antimicrob Chemother       Date:  1999-01       Impact factor: 5.790

Review 5.  Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.

Authors:  J J Schentag
Journal:  J Chemother       Date:  1999-12       Impact factor: 1.714

6.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; M Corrado
Journal:  JAMA       Date:  1998-01-14       Impact factor: 56.272

7.  Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease.

Authors:  I R Friedland
Journal:  Pediatr Infect Dis J       Date:  1995-10       Impact factor: 2.129

Review 8.  Acute otitis media: management and surveillance in an era of pneumococcal resistance--a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.

Authors:  S F Dowell; J C Butler; G S Giebink; M R Jacobs; D Jernigan; D M Musher; A Rakowsky; B Schwartz
Journal:  Pediatr Infect Dis J       Date:  1999-01       Impact factor: 2.129

9.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

Review 10.  Unique aspects of quinolone pharmacokinetics.

Authors:  H Lode; G Höffken; K Borner; P Koeppe
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.